European drug association criticizes EU plan for disclosure rules

07/1/2013 | Chemical & Engineering News

The European Federation of Pharmaceutical Industries and Associations said that proposals by the European Medicines Agency to make clinical trial data public could compromise sensitive proprietary research and place their companies at a competitive disadvantage. The EMA draft plan, scheduled to go into effect by Jan. 1, is open for three months of comments. The federation says it is preparing its own alternative for publishing trial results.

View Full Article in:

Chemical & Engineering News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC